To clarify the long-term efficacy, safety and the cytokine network-modulating effects of tacrolimus in myasthenia gravis, medical records of 86 newly diagnosed consecutive patients and nine steroid-dependent patients were retrospectively reviewed, and peripheral blood mononuclear cells (PBMC) were cultured for the cytokine profile. Steroid reduction effects were observed by using tacrolimus, and no serious adverse effects were observed. The culture study showed reduced IL-12, IL-17, IFN-γ, GM-CSF, TNF-α and MIP-1β, and elevated IL-10 in the PBMC from patients who received tacrolimus, which suggests inhibition of T cells and macrophages, and enhancement of type 1 regulatory T cells.
Introduction
Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies against the nicotinic acetylcholine receptor (AChR) cause a transmission failure at neuromuscular junctions (Conti-Fine et al., 2006) . The production of these antibodies in B cells depends upon AChR-specific T cells (Fujii and Lindstrom, 1988) . Long-term corticosteroid treatment markedly improves the outcome of MG therapy (Pascuzzi et al., 1984) . Additionally, non-steroidal immunosuppressive agents, such as cyclosporine (Bonifati and Angelini, 1997), azathioprine (Palace et al., 1998) , and cyclophosphamide (De Feo et al., 2002) , have been used in combination with steroids.
Recently, tacrolimus has also become available for the treatment of MG. It has been reported in non-controlled studies that low-dose administration of tacrolimus is effective and safe in combination with steroids for MG (Evoli et al., 2002; Konishi et al., 2005; Yoshikawa et al., 2002a) . A distinguishing feature of tacrolimus is that its effect appears early after its administration. The long-term efficacy of tacrolimus has also been reported (Konishi et al., 2005; Ponseti et al., 2005) . Tacrolimus is a macrolide immunosuppressive agent isolated from Streptomyces tsukubaensis (Kino et al., 1987a) and has been used in the field of organ transplantation (Undre et al., 1999) . It exhibits immunosuppressive activity by inhibiting production of interleukin (IL)-2 (Flanagan et al., 1991) , which is an early T cell activation factor and stimulates cell growth and differentiation (Tocci et al., 1989) . However, the pharmacological effects of tacrolimus are not fully understood. It is thought that there is a significant correlation between IgG production and productions of IL-5 and IL-6 by cultured peripheral blood mononuclear cells (PBMCs) from patients with MG (Yoshikawa et al., 2002b) . However the effects of tacrolimus on cytokine production by cultured PBMCs have not been evaluated.
In this study, we examined the long-term efficacy and safety of tacrolimus for the treatment of newly diagnosed MG patients in a retrospective case-controlled study. We also examined its efficacy and safety for steroid-dependent patients. In addition, we studied cytokine or chemokine production profiles in PBMCs to clarify the pharmacological effects of tacrolimus in patients with MG. Journal of Neuroimmunology 195 (2008) 108 -115 www.elsevier.com/locate/jneuroim
